| 1AHW | C:4-106; C:107-211; F:4-106; F:107-211 | A COMPLEX OF EXTRACELLULAR DOMAIN OF TISSUE FACTOR WITH AN INHIBITORY FAB (5G9) |
| 1BOY | A:3-106; A:107-213 | EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR |
| 1DAN | T:,U:91-106; U:107-210 | COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR |
| 1FAK | T:6-106; T:107-210 | HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT |
| 1J9C | T:1-106; T:107-210 | CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX |
| 1JPS | T:5-106; T:107-211 | CRYSTAL STRUCTURE OF TISSUE FACTOR IN COMPLEX WITH HUMANIZED FAB D3H44 |
| 1O5D | T:6-106; T:107-205 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
| 1TFH | A:5-106; A:107-211; B:5-106; B:107-210 | EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR |
| 1UJ3 | C:606-706; C:707-810 | CRYSTAL STRUCTURE OF A HUMANIZED FAB FRAGMENT OF ANTI-TISSUE-FACTOR ANTIBODY IN COMPLEX WITH TISSUE FACTOR |
| 1W0Y | T:6-106; T:107-210 | TF7A_3771 COMPLEX |
| 1W2K | T:6-108; T:109-209 | TF7A_4380 COMPLEX |
| 1WQV | T:6-108; T:109-209 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE |
| 1WSS | T:6-108; T:109-209 | HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4 |
| 1WTG | T:6-108; T:109-209 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE |
| 1WUN | T:6-108; T:109-209 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE |
| 1WV7 | T:6-108; T:109-209 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE |
| 1Z6J | T:6-108; T:109-209 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR |
| 2A2Q | T:6-106; T:107-210 | COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+ |
| 2AEI | T:6-108; T:109-209 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID |
| 2AER | T:6-108; T:109-209 | CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX. |
| 2B7D | T:6-106; T:107-205 | FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL |
| 2B8O | T:6-106; T:107-210 | CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX |
| 2C4F | U:91-210 | CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121 |
| 2F9B | T:6-106; T:107-205 | DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS |
| 2FIR | T:6-106; T:107-210 | CRYSTAL STRUCTURE OF DFPR-VIIA/STF |
| 2FLB | T:6-106; T:107-205 | DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR |
| 2FLR | T:6-106; T:107-205 | NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS |
| 2HFT | A:1-106; A:107-211 | THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR AT 1.7 ANGSTROMS RESOLUTION |
| 2ZP0 | T:6-108; T:109-209 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE |
| 3TH2 | T:6-106; T:107-210 | MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+ |
| 3TH3 | T:6-106; T:107-209 | MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+ |
| 3TH4 | T:6-106; T:107-210 | MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+ |
)
)